Partner Therapeutics, Inc.

Privately held: no public share price · United States

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Sargramostim(Leukine)
Approved
GM-CSF receptorProtein / enzyme therapeutic
Acute Myeloid Leukemia
Zenocutuzumab(Bizengri)
Approved
HER2; HER3 (blocks NRG1 binding to HER3)Multispecific antibody
Non-Small Cell Lung CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma
Cholangiocarcinoma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Zenocutuzumab · BizengriPhase 2Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Est. primary completion 2026-12-31 · NCT02912949 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 May 2026ApprovalZenocutuzumabFDA Boxed Warning on Bizengri (BLA761352)
US, FDA · FDA · Source ↗

Financial reports

No financial reports recorded.